Applied Clinical Trials
Updates in dermatology trials.
Skin is the largest organ of the human body, and its complex and sensitive nature toward various foreign and internal factors makes it highly susceptible to a number of diseases and disorders.
The result of these foreign and internal factors (environmental, physical, microbial, hormonal, and others) is critical conditions and related symptoms.
Pharmaceutical companies conduct clinical trials based on factors such as a promising therapeutic area, unmet needs for a particular indication, and the presence of a significant patient population.
The number of patients recruited for major indications from 2000 to 2010.
Currently, there are many indications for which no appropriate treatment is available. Therefore, pharmaceutical companies are currently analyzing the potential of launching new therapies and tapping the potential market.
An analysis of patients recruited for clinical trials which were "completed," "ongoing," and/or "started" during 2000–2010, showed that patient recruitment, among all the major indications under dermatology, was highest for acne vulgaris.
GBI Research discovered that the highest number of patients were recruited for clinical trials for acne vulgaris, atopic dermatitis, candidiasis alopecia, and herpes zoster—the figure depicts the results.
A study conducted on the number of patients recruited for clinical trials in dermatology shows that the total number of patients recruited for acne vulgaris clinical trials accounted for 48% of the total dermatology clinical trial recruitments, which accounted for a greater patient share than that of atopic dermatitis with 25%. The numbers of patients recruited for herpes zoster were 17%, followed by candidiasis with 9%, while alopecia clinical trial recruitment accounted for 1% of the total dermatology clinical recruitments.
In the dermatology sector, most companies coordinate their research and development (R&D) activities to constantly expand their product pipeline with innovative drugs.
Although there is a consistent and continuous threat from generics and other alternatives, companies in the dermatology therapy area are not reluctant to invest in R&D and are focused on offering new products to the market.
In addition to the threat from generics, patient recruitment is another major challenge for clinical research organizations. Patient recruitment is the most time-consuming process involved in clinical trials. Recruitment of patients is more difficult than treating them.
High competition is observed among the companies recruiting subjects with similar dermatological conditions. However, to achieve better results and easy determination of drug efficacy, the selection of subjects should be based upon the variability in dermatological symptoms/specification of the disease in patients.
This can be achieved by following physician referral, advertisements, and by conducting patient awareness programs through seminars and other means.
Adequate patient recruitment is necessary to ensure a successful trial within the scheduled time limit. Patient recruitment and enrollment within the proposed time limit enables the company to launch new products ahead of its competitors and maximize revenues from them.
Following the ethical guidelines established by the relevant regulatory authorities is one of the more important requirements in avoiding external barriers to the progress of trials.
— Syed Faiyaz Razvi is a Clinical Trials Analyst at GBI Research
Including Women of Childbearing Age in Clinical Research
March 26th 2024In recognition of International Women's Month, we're featuring this recent talk between Associate Editor Miranda Schmalfuhs and Marie Teil, Global Head of UCB’s Women of Childbearing Age Program. They speak about the specific challenges women with chronic illnesses face when accessing appropriate treatment and participating in clinical trials, UCB's Women of Childbearing Age Program and it’s most successful strategies, and much more.
Improving Engagement While Maintaining Data Integrity & Validity
March 19th 2024In recognition of Women's Health Month, we're featuring this recent talk between Associate Editor Miranda Schmalfuhs and uMotif's Chief Product Officer, Julia Lakeland, discuss new technologies improving patient engagement and reducing the emotional and logistical burdens of participation, ethical considerations that should be addressed when implementing those technologies, while ensuring patient privacy, and much more.
The State of the Opioid Epidemic
March 26th 2024In part 1 of this video interview, Greg Sturmer, co-founder and CEO of Elysium Therapeutics discusses the current state of opioid usage including how pain treatment is often mismanaged and how the industry can adopt greater safety standards in developing pain therapies.